サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1655404

糖尿病黄斑浮腫治療の世界市場

Diabetic Macular Edema Treatment

出版日
ページ情報
英文 192 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
糖尿病黄斑浮腫治療の世界市場
出版日: 2025年02月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

糖尿病黄斑浮腫治療の世界市場は2030年までに55億米ドルに達する

2024年に48億米ドルと推定される糖尿病黄斑浮腫治療の世界市場は、2024～2030年の分析期間にCAGR 2.2%で成長し、2030年には55億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗VEGF薬は、CAGR 2.5%を記録し、分析期間終了時には27億米ドルに達すると予想されます。副腎皮質ステロイド分野の成長率は、分析期間中CAGR 2.0%と推定されます。

米国市場は13億米ドルと推定、中国はCAGR 1.9％で成長予測

米国の糖尿病黄斑浮腫治療市場は、2024年に13億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを1.9%として、2030年までに8億5,580万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.2%と1.4%と予測されています。欧州では、ドイツがCAGR 1.6%で成長すると予測されています。

世界の糖尿病黄斑浮腫治療市場- 主要動向と促進要因まとめ

糖尿病黄斑浮腫とは何か、なぜ効果的な治療が重要なのか？

糖尿病黄斑浮腫（Diabetic Macular Edema：DME）は、糖尿病患者が罹患する重篤な眼疾患で、鋭い視力を担う網膜の中心部である黄斑部の腫脹を引き起こします。糖尿病の有病率が世界的に上昇するにつれて、DMEはますます一般的な合併症となり、放置すると視力低下の重大なリスクをもたらします。DMEの効果的な治療は、視力を維持し自立を可能にすることで、何百万人もの患者の生活の質に直接影響を与えるため、非常に重要です。現在の治療法には、抗VEGF薬の硝子体内注射、副腎皮質ステロイド、レーザー治療などがあり、それぞれ病態の異なる側面を標的としています。研究の進歩に伴い、より新しい治療法が開発され、有効性の向上、副作用の軽減、そしてこの衰弱状態に苦しむ患者のより持続的な救済を提供しています。

治療技術の進歩はDMEの治療成績をどのように改善しているか？

医療技術と薬理学の進歩により、糖尿病黄斑浮腫患者の治療成績は著しく向上しています。抗VEGF（血管内皮増殖因子）療法のイントロダクションはDME治療に革命をもたらし、黄斑浮腫の原因となる異常な血管の成長を阻害することで、より的を絞った治療法を提供しています。これらの治療法は、視力を著しく改善し、網膜の厚さを減少させることが示されています。さらに、徐放性コルチコステロイドインプラントは、抗VEGF治療で十分な効果が得られない患者に対する有望な選択肢として浮上しており、少ない注射回数で長期的な管理が可能です。さらに、遺伝子治療やその他の新しいアプローチに関する現在進行中の研究は、DMEの根本的な原因に対処することを目的としており、将来的にはより耐久性のある包括的な治療ソリューションを提供できる可能性があります。

糖尿病黄斑浮腫の管理にはどのような課題があるか？

糖尿病黄斑浮腫の管理には、患者にとってもヘルスケアプロバイダーにとってもいくつかの課題があります。主な課題の1つは、この疾患が慢性的であることで、視機能を維持するためには継続的なモニタリングと繰り返しの治療が必要です。治療レジメンを遵守することは患者にとって困難であり、特に頻繁に硝子体内注射を行う必要がある場合には、治療が中断され、治療成績が最適化されない可能性があります。さらに、現在の治療に対する反応にはばらつきがあるため、標準的な治療では十分な改善が得られない患者もいることから、DME管理に対する個別化アプローチの必要性が強調されています。もう一つの課題は、特に糖尿病とその合併症の負担が急増している中低所得国において、先進的な治療法を利用しやすく、経済的な負担が少ないことです。

糖尿病黄斑浮腫治療市場の成長はいくつかの要因別もたらされる

糖尿病黄斑浮腫治療市場の成長は、世界の糖尿病有病率の上昇、治療技術の進歩、糖尿病眼疾患に対する認識とスクリーニングの向上など、いくつかの要因によって牽引されています。糖尿病人口の拡大が続く中、効果的なDME治療に対する需要もそれに応じて高まることが予想されます。より長時間作用する抗VEGF薬や徐放性ドラッグデリバリーシステムの開発などの技術革新も、副作用が少なく患者の利便性が高い改善された治療選択肢を提供することで、市場開拓に拍車をかけています。さらに、糖尿病網膜症や黄斑浮腫の早期発見と介入を目的とした公衆衛生上の取り組みが診断症例数を増加させ、治療需要をさらに押し上げています。これらの要因は、新たな治療法に関する継続的な研究と相まって、DME治療の将来的な展望を形成し、急速に進化するダイナミックな市場となっています。

セグメント

製品（抗VEGF薬、副腎皮質ステロイド薬、その他の製品）

調査対象企業の例（全38社）

  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Bausch & Lomb, Inc.
  • Boehringer Ingelheim International GmbH
  • Genentech, Inc.
  • IRIDEX Corporation
  • Novartis International AG
  • Pfizer, Inc.
  • Quantel Medical
  • Regeneron Pharmaceuticals, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP13146

Global Diabetic Macular Edema Treatment Market to Reach US$5.5 Billion by 2030

The global market for Diabetic Macular Edema Treatment estimated at US$4.8 Billion in the year 2024, is expected to reach US$5.5 Billion by 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Anti-VEGF, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Corticosteroid segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 1.9% CAGR

The Diabetic Macular Edema Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$855.8 Million by the year 2030 trailing a CAGR of 1.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Diabetic Macular Edema Treatment Market - Key Trends & Drivers Summarized

What Is Diabetic Macular Edema and Why Is Effective Treatment Critical?

Diabetic Macular Edema (DME) is a severe eye condition that affects individuals with diabetes, leading to swelling in the macula, the central part of the retina responsible for sharp vision. As diabetes prevalence rises globally, DME has become an increasingly common complication, posing a significant risk of vision loss if left untreated. Effective treatment for DME is crucial as it directly impacts the quality of life for millions of patients by preserving their vision and enabling them to maintain independence. Current treatment options include intravitreal injections of anti-VEGF agents, corticosteroids, and laser therapy, each targeting different aspects of the disease's pathology. As research advances, newer therapies are being developed to improve efficacy, reduce side effects, and provide more sustained relief for patients suffering from this debilitating condition.

How Are Advancements in Treatment Technologies Improving DME Outcomes?

Advancements in medical technologies and pharmacology are significantly improving the outcomes for patients with Diabetic Macular Edema. The introduction of anti-VEGF (vascular endothelial growth factor) therapies has revolutionized DME treatment, offering a more targeted approach to managing the condition by inhibiting the abnormal blood vessel growth that leads to macular swelling. These therapies have been shown to significantly improve visual acuity and reduce retinal thickness. Additionally, sustained-release corticosteroid implants have emerged as a promising option for patients who do not respond adequately to anti-VEGF treatments, providing long-term management with fewer injections. Furthermore, ongoing research into gene therapy and other novel approaches aims to address the underlying causes of DME, potentially offering more durable and comprehensive treatment solutions in the future.

What Challenges Exist in Managing Diabetic Macular Edema?

Managing Diabetic Macular Edema presents several challenges, both for patients and healthcare providers. One of the primary challenges is the chronic nature of the condition, which requires ongoing monitoring and repeated treatments to maintain visual function. Adherence to treatment regimens can be difficult for patients, especially when frequent intravitreal injections are necessary, leading to potential lapses in care and suboptimal outcomes. Additionally, the variability in response to current treatments underscores the need for personalized approaches to DME management, as some patients may not experience sufficient improvement with standard therapies. Another challenge is the accessibility and affordability of advanced treatments, particularly in low- and middle-income countries, where the burden of diabetes and its complications is growing rapidly.

Growth in the Diabetic Macular Edema Treatment Market Is Driven by Several Factors

The growth in the Diabetic Macular Edema treatment market is driven by several factors, including the rising global prevalence of diabetes, advancements in treatment technologies, and increased awareness and screening for diabetic eye diseases. As the diabetic population continues to expand, the demand for effective DME treatments is expected to rise correspondingly. Technological innovations, such as the development of longer-acting anti-VEGF agents and sustained-release drug delivery systems, are also fueling market growth by offering improved treatment options with fewer side effects and greater patient convenience. Additionally, public health initiatives aimed at early detection and intervention for diabetic retinopathy and macular edema are increasing the number of diagnosed cases, further driving the demand for treatment. These factors, combined with ongoing research into new therapeutic modalities, are poised to shape the future landscape of DME treatment, making it a rapidly evolving and dynamic market.

SCOPE OF STUDY:

The report analyzes the Diabetic Macular Edema Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Anti-VEGF, Corticosteroid, Other Products)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 38 Featured) -

  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Bausch & Lomb, Inc.
  • Boehringer Ingelheim International GmbH
  • Genentech, Inc.
  • IRIDEX Corporation
  • Novartis International AG
  • Pfizer, Inc.
  • Quantel Medical
  • Regeneron Pharmaceuticals, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Diabetic Macular Edema Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Global Economic Update
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Diabetes Drives Growth in Diabetic Macular Edema Treatment Market
    • Technological Advancements in Ophthalmic Imaging Propel Demand for Early Diagnosis and Treatment
    • Increased Government Funding for Diabetes-related Research Expands Addressable Market for Treatments
    • Rising Awareness of Diabetic Eye Complications Spurs Demand for Advanced Treatment Options
    • Emergence of Novel Therapeutics Strengthens Business Case for Targeted Treatments
    • Technological Innovations in Drug Delivery Systems Propel Growth in Injectable Treatments
    • Expanding Availability of Anti-VEGF Therapies Drives Adoption in Diabetic Macular Edema Treatment
    • Improved Patient Outcomes with Combination Therapies Accelerates Treatment Adoption
    • Increasing Investment in Biologics Spurs Growth in Long-lasting DME Treatment Solutions
    • Rising Focus on Minimally Invasive Treatments Generates Demand for Innovative Surgical Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Diabetic Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Diabetic Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Anti-VEGF by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Corticosteroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Corticosteroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Corticosteroid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 13: World Diabetic Macular Edema Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: USA 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: Canada 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
  • JAPAN
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: Japan 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
  • CHINA
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: China 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
  • EUROPE
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Diabetic Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Diabetic Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Europe 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
  • FRANCE
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: France 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
  • GERMANY
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Germany 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Italy 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: UK 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Rest of Europe Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Rest of Europe 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Asia-Pacific Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Asia-Pacific 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Rest of World Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Rest of World 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030

IV. COMPETITION